Almirall has reached a regulatory milestone after the European Medicines Agency (EMA) accepted its application to expand the use of Ebglyss (lebrikizumab) for children and adolescents aged 6 months to under 18 years with moderate-to-severe atopic dermatitis weighing less than 40 kg. The submission is supported by pediatric clinical trial data demonstrating improvements in disease severity, skin clearance, itch relief, and quality of life, potentially broadening treatment options for younger patients across Europe.

Almirall is seeking to extend the approved use of its biologic therapy Ebglyss (lebrikizumab) to younger pediatric patients after the European Medicines Agency accepted its application for regulatory review. The filing represents another step in expanding biologic treatment options for children living with moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease that often begins during infancy.

The application covers children and adolescents aged 6 months to under 18 years who weigh below 40 kilograms. If approved, the indication would significantly extend access beyond the medicine’s current authorization in Europe for adults and adolescents aged 12 years and older.

Regulatory acceptance does not represent market approval but confirms that the EMA considers the submission sufficiently complete to begin its scientific assessment. During the review process, regulators will evaluate whether available clinical evidence demonstrates an appropriate balance between efficacy and safety for younger patients.

The submission is supported primarily by findings from the ADorable-1 pediatric study and the ADorable-2 long-term extension trial. According to Almirall, ADorable-1 met both co-primary endpoints and key secondary endpoints, with children receiving lebrikizumab experiencing meaningful improvements in skin clearance, disease severity, itching symptoms, and health-related quality of life compared with placebo.

Equally important in pediatric medicine, the company reported that the therapy’s safety profile remained consistent with previous studies conducted in adolescents and adults. No new safety concerns were identified during the interim analysis, an important consideration when evaluating long-term biologic treatment in younger children.

Atopic dermatitis, commonly referred to as eczema, is among the most prevalent chronic inflammatory skin conditions worldwide. The disease frequently develops during infancy, with approximately 60% of cases appearing within the first year of life and up to 85% developing before five years of age, making early intervention an important focus of dermatology research.

Beyond visible skin symptoms, moderate-to-severe atopic dermatitis can substantially affect sleep quality, mental well-being, school performance, and family life. Persistent itching and recurrent inflammation often require long-term disease management strategies aimed at controlling symptoms while minimizing treatment-related risks.

Lebrikizumab is a monoclonal antibody designed to selectively inhibit interleukin-13 (IL-13), a cytokine recognized as a central driver of type 2 inflammation associated with atopic dermatitis. By targeting IL-13 rather than broadly suppressing the immune system, biologic therapies seek to reduce inflammation while offering more targeted disease control than conventional systemic treatments.

The regulatory filing also reflects broader momentum within dermatology toward expanding precision medicine for pediatric populations. Over the past several years, pharmaceutical companies including Eli Lilly, Sanofi, Regeneron, Pfizer, and AbbVie have invested heavily in biologic and targeted therapies for chronic inflammatory diseases, creating a more competitive treatment landscape for patients with moderate-to-severe eczema.

Under its licensing agreement, Almirall holds commercialization rights for lebrikizumab across Europe, while Eli Lilly and Company retains development and commercialization rights in the United States and most international markets outside Europe.

According to GlobalData, the market for biologic therapies treating inflammatory skin diseases is expected to continue expanding as physicians increasingly adopt targeted immunology treatments over traditional systemic therapies. Meanwhile, Evaluate Pharma projects continued growth across immunology and dermatology biologics, supported by expanding indications, earlier diagnosis, and improved patient access.

For clinicians, expanding treatment eligibility into younger age groups could provide additional therapeutic options for patients whose disease remains inadequately controlled with topical corticosteroids or other conventional therapies. Earlier disease control may also help reduce long-term disease burden, improve quality of life, and potentially limit complications associated with persistent inflammation.

The EMA’s review will now determine whether the available pediatric evidence supports extending Ebglyss’ European marketing authorization. While the outcome remains subject to regulatory evaluation, the filing illustrates the pharmaceutical industry’s continued focus on bringing targeted biologic therapies to pediatric patients with chronic inflammatory diseases.

Market Landscape

The dermatology market is increasingly shifting toward precision biologic therapies that target specific inflammatory pathways responsible for chronic skin diseases. Advances in immunology have expanded treatment options for conditions including atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Major pharmaceutical companies such as Eli Lilly, Sanofi, Regeneron, Pfizer, and AbbVie continue investing in biologic innovation as healthcare providers seek therapies that deliver durable disease control with well-characterized safety profiles. Pediatric indications represent an important growth area as regulators encourage clinical research involving younger patient populations.

Strategic Outlook

The EMA’s acceptance of Almirall’s pediatric application reflects growing regulatory emphasis on expanding advanced therapies for children with chronic inflammatory diseases. If approved, lebrikizumab could provide physicians with another targeted biologic option for managing moderate-to-severe atopic dermatitis in younger patients.

The filing also reinforces broader industry trends toward earlier intervention, precision immunology, and expanded biologic access across pediatric dermatology.

Top Insights

• The EMA has accepted Almirall’s application to expand Ebglyss use to children aged six months and older with moderate-to-severe atopic dermatitis.
• Clinical data from ADorable-1 demonstrated significant improvements in skin clearance, itch reduction, disease severity, and quality of life compared with placebo.
• Interim safety findings remained consistent with the established profile previously observed in adults and adolescents receiving lebrikizumab.
• The filing supports broader industry efforts to expand biologic therapies into pediatric dermatology and earlier disease intervention.
• Approval could provide physicians with an additional targeted IL-13 inhibitor for managing severe childhood eczema across Europe.

Get in touch with our Adtech experts